The global Paromomycin (CAS 7542-37-2) market was valued at USD 120.5 million in 2022 and is projected to reach USD 175.6 million by 2030, growing at a CAGR of 4.5% from 2024 to 2030. The demand for Paromomycin is primarily driven by its application in treating parasitic infections such as amebiasis and leishmaniasis, as well as its use in combination therapies for multi-drug resistant tuberculosis. In addition, the expanding healthcare infrastructure in emerging markets, coupled with increasing awareness about parasitic diseases, is further propelling market growth. The rise in global travel and the associated increase in tropical and parasitic infections are expected to contribute to the continued demand for Paromomycin over the forecast period.
Further contributing to the market's expansion is the rising prevalence of neglected tropical diseases, which has spurred efforts to enhance treatment options and drug availability. The market is also witnessing innovations in drug formulations and delivery methods, which are expected to positively impact the demand for Paromomycin. Moreover, government initiatives aimed at combating infectious diseases in developing regions are expected to enhance the adoption of Paromomycin. The increasing focus on improving the global healthcare system and access to medicines will likely sustain the market’s growth trajectory through 2030.
Download Full PDF Sample Copy of Market Report @
Paromomycin (CAS 7542-37-2) Market Research Sample Report
Paromomycin (CAS 7542-37-2) is an antibiotic used primarily in the treatment of intestinal amebiasis and other parasitic infections. The market for Paromomycin is segmented based on its applications, which include both therapeutic uses and formulations such as Paromomycin Sulfate and Paromomycin Injection. Each of these subsegments caters to specific needs within the pharmaceutical and healthcare sectors, and their growth is driven by various factors, including the increasing prevalence of parasitic diseases, healthcare infrastructure, and the rising demand for effective antimicrobial therapies.
Paromomycin Sulfate is a broad-spectrum aminoglycoside antibiotic commonly used to treat intestinal amebiasis, leishmaniasis, and other parasitic infections. The global demand for Paromomycin Sulfate has been on the rise due to increasing incidences of parasitic diseases in tropical and subtropical regions. The drug is often used as an oral formulation and can also be administered for the treatment of infections caused by various protozoa, particularly in underdeveloped regions where parasitic diseases remain a significant public health concern. It has also demonstrated efficacy in treating visceral leishmaniasis, a deadly disease caused by protozoan parasites, thus expanding its therapeutic applications.
In terms of market dynamics, the Paromomycin Sulfate segment is expected to grow steadily due to continued investments in healthcare in developing countries, where parasitic diseases remain prevalent. Moreover, as awareness regarding the effectiveness of Paromomycin Sulfate increases, especially in the treatment of multidrug-resistant infections, the demand for this drug is likely to experience a surge. The increasing global focus on improving access to essential medicines in underserved areas and rising healthcare spending are likely to further stimulate the demand for this formulation, contributing to the market’s overall growth in the coming years.
Paromomycin Injection is used in the treatment of severe or systemic infections caused by susceptible organisms. This injectable form of Paromomycin is primarily utilized in hospital settings or under the supervision of healthcare professionals, especially for patients who cannot take oral medications. It is often prescribed for conditions such as visceral leishmaniasis and other severe forms of parasitic infections. This formulation is critical in treating patients with infections that require rapid and effective antibiotic treatment to prevent complications and death. Paromomycin Injection is considered essential in regions where certain parasitic infections are endemic, and the need for effective treatment is paramount.
The Paromomycin Injection market is anticipated to grow due to rising healthcare infrastructure and technological advancements in the formulation of injectables. As the demand for more effective treatments for parasitic infections increases, the market for injectable formulations, including Paromomycin Injection, is likely to see a notable rise. Hospitals and healthcare facilities in emerging economies are increasingly adopting injectable antibiotics, and this trend is expected to boost the growth of this subsegment. The development of new therapies and partnerships between pharmaceutical companies and government agencies to increase access to injectable Paromomycin in low-resource settings will play a key role in expanding the market for this formulation in the coming years.
The Paromomycin market is witnessing several key trends and opportunities that are shaping its future growth. One of the primary trends is the increasing focus on antimicrobial resistance (AMR) and the need for effective treatments for drug-resistant infections. Paromomycin, being an aminoglycoside antibiotic, is gaining attention due to its efficacy against certain resistant pathogens, which positions it well in the fight against AMR. Governments and global health organizations are pushing for greater research and development of antibiotics like Paromomycin to combat these growing threats, which could drive increased demand for Paromomycin-based treatments in the coming years.
Another opportunity lies in the expansion of Paromomycin’s use in tropical and subtropical regions where parasitic infections remain endemic. Countries in sub-Saharan Africa, Southeast Asia, and Latin America represent significant markets for Paromomycin products, including both oral and injectable formulations. Public-private partnerships aimed at improving access to essential medicines in these regions are likely to support the growth of the Paromomycin market. Additionally, the ongoing research into combination therapies involving Paromomycin for treating more complex infections could further enhance its clinical utility and market prospects.
What is Paromomycin used for?
Paromomycin is primarily used to treat intestinal amebiasis and other parasitic infections like leishmaniasis and cryptosporidiosis.
How does Paromomycin work?
Paromomycin works by inhibiting protein synthesis in bacterial cells, leading to the death of the bacteria and parasitic organisms.
Is Paromomycin available in oral form?
Yes, Paromomycin is available in oral formulations, such as Paromomycin Sulfate, to treat intestinal infections.
Can Paromomycin be used to treat leishmaniasis?
Yes, Paromomycin is effective in the treatment of visceral leishmaniasis, a parasitic infection caused by protozoa.
What are the side effects of Paromomycin?
Common side effects of Paromomycin include nausea, vomiting, and abdominal discomfort. Rare side effects may include kidney toxicity and hearing loss.
What is the market outlook for Paromomycin?
The Paromomycin market is expected to grow, driven by increasing healthcare access in developing regions and rising demand for effective treatments for parasitic infections.
Is Paromomycin safe for pregnant women?
Paromomycin is classified as a pregnancy category C drug, meaning it should only be used if the potential benefits outweigh the risks.
Can Paromomycin be administered intravenously?
Yes, Paromomycin is available as an injectable form for the treatment of severe infections, including visceral leishmaniasis.
How is Paromomycin different from other antibiotics?
Paromomycin is an aminoglycoside antibiotic with a unique mechanism that targets bacterial protein synthesis, which is effective against certain parasitic infections.
What are the opportunities for Paromomycin in emerging markets?
Paromomycin has significant opportunities in emerging markets, particularly in regions with high rates of parasitic diseases, such as sub-Saharan Africa and Southeast Asia.
For More Information or Query, Visit @ Paromomycin (CAS 7542-37-2) Market Size And Forecast 2025-2030